🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: SKB264

Found 67 matching trials

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

PHASE3

The primary objective of the study is to compare sacituzumab tirumotecan co...

Status

Recruiting

Location

Mayo Clinic in Arizona - Phoenix ( Site 0147)

Start Date

2023-12-15

Trial ID

NCT06170788

Treatments Being Tested

Sacituzumab tirumotecan Pembrolizumab Supportive care measures

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

PHASE3

The purpose of this study is to evaluate sacituzumab tirumotecan versus pem...

Status

Active Not Recruiting

Location

Kaiser Permanente - Oakland ( Site 0054)

Start Date

2024-06-11

Trial ID

NCT06305754

Treatments Being Tested

Sacituzumab tirumotecan Pemetrexed Carboplatin H1 Receptor Antagonist H2 Receptor Antagonist Acetaminophen (or equivalent)Dexamethasone (or equivalent)Steroid Mouthwash (dexamethasone or equivalent)

ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma

PHASE2

This is a single-arm, single-center, exploratory clinical study. The study ...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2026-05-01

Trial ID

NCT07579598

Treatments Being Tested

Becotatug Vedotin SBRT Becotatug Vedotin or Sacituzumab Tirumotecan

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

PHASE3

This study will compare how safe and effective sacituzumab tirumotecan is v...

Status

Active Not Recruiting

Location

Banner MD Anderson Cancer Center ( Site 0119)

Start Date

2024-05-03

Trial ID

NCT06356311

Treatments Being Tested

Sacituzumab tirumotecan Trifluridine-Tipiracil Irinotecan Paclitaxel Docetaxel Rescue medications Supportive care measures

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

PHASE3

Researchers are looking for new ways to treat people with endometrial cance...

Status

Active Not Recruiting

Location

USA Mitchell Cancer Institute ( Site 4142)

Start Date

2023-12-06

Trial ID

NCT06132958

Treatments Being Tested

Sacituzumab tirumotecan Doxorubicin Paclitaxel Nab-paclitaxel Rescue medications

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

PHASE1

Researchers are looking for new ways to treat esophageal squamous cell carc...

Status

Recruiting

Location

UPMC Hillman Cancer Center ( Site 1904)

Start Date

2025-07-30

Trial ID

NCT06780111

Treatments Being Tested

Pembrolizumab I-DXd Leucovorin Levoleucovorin 5-Fluorouracil (5-FU)Oxaliplatin Sacituzumab tirumotecan Rescue Medication

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

PHASE2

The main goals are after treatment given before surgery, to measure the num...

Status

Recruiting

Location

Southern Cancer Center (SCC) ( Site 8004)

Start Date

2025-03-20

Trial ID

NCT06788912

Treatments Being Tested

Pembrolizumab (neoadjuvant)Cisplatin Gemcitabine Pemetrexed Sacituzumab tirumotecan H1 receptor antagonist H2 receptor antagonist Acetaminophen (or equivalent)Dexamethasone (or equivalent)Carboplatin Pembrolizumab (adjuvant)Paclitaxel Steroid mouthwash (dexamethasone or equivalent)

A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

PHASE2

Researchers are looking for new ways to treat certain types of advanced sol...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2026-09-30

Trial ID

NCT07785609

Treatments Being Tested

MK-2010 Sacituzumab tirumotecan Histamine H1 Receptor Antagonist Histamine H2 Receptor Antagonist Acetaminophen (or equivalent)Dexamethasone (or equivalent)Steroid mouthwash (dexamethasone or equivalent)Epinephrine

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

PHASE3

Researchers are looking for new ways to treat people with proficient mismat...

Status

Recruiting

Location

University of South Alabama, Mitchell Cancer Institute ( Site 6033)

Start Date

2025-05-22

Trial ID

NCT06952504

Treatments Being Tested

Pembrolizumab Carboplatin Paclitaxel Docetaxel Sacituzumab Tirumotecan Cisplatin

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

PHASE3

The purpose of this study is to evaluate the efficacy and safety of SKB264 ...

Status

Recruiting

Location

The Fifth Medical Center of the Chinese PLA General Hospital

Start Date

2025-07-18

Trial ID

NCT07071337

Treatments Being Tested

SKB264 Nab-paclitaxel Paclitaxel Capecitabine

Previous Next